These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26165417)

  • 21. Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
    Julie DA; Oh JH; Apte AP; Deasy JO; Tom A; Wu AJ; Goodman KA
    Acta Oncol; 2016; 55(2):208-16. PubMed ID: 25984929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
    Oh IJ; Kim KS; Kim YC; Ban HJ; Kwon YS; Kim YI; Lim SC; Chung WK; Nam TK; Song JY; Yoon MS; Ahn SJ
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1247-54. PubMed ID: 24091849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
    Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer.
    Niho S; Kubota K; Nihei K; Sekine I; Sumi M; Sekiguchi R; Funai J; Enatsu S; Ohe Y; Tamura T
    Clin Lung Cancer; 2013 Jan; 14(1):62-9. PubMed ID: 22633219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM
    Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
    Machtay M; Duan F; Siegel BA; Snyder BS; Gorelick JJ; Reddin JS; Munden R; Johnson DW; Wilf LH; DeNittis A; Sherwin N; Cho KH; Kim SK; Videtic G; Neumann DR; Komaki R; Macapinlac H; Bradley JD; Alavi A
    J Clin Oncol; 2013 Oct; 31(30):3823-30. PubMed ID: 24043740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
    Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
    Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
    Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
    Seung SK; Ross HJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):802-9. PubMed ID: 18762390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.
    Wang L; Correa CR; Zhao L; Hayman J; Kalemkerian GP; Lyons S; Cease K; Brenner D; Kong FM
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1383-90. PubMed ID: 18929449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
    Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
    J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
    Bastos BR; Hatoum GF; Walker GR; Tolba K; Takita C; Gomez J; Santos ES; Lopes G; Raez LE
    J Thorac Oncol; 2010 Apr; 5(4):533-9. PubMed ID: 20357618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
    Flentje M; Huber RM; Engel-Riedel W; Andreas S; Kollmeier J; Staar S; Dickgreber N; Vaissiere N; De Almeida C; Edlich B; Fietkau R
    Strahlenther Onkol; 2016 Apr; 192(4):216-22. PubMed ID: 26809652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based chemotherapy in stage III non-small-cell lung cancer.
    Kaderbhaï CG; Coudert B; Bertaut A; Adnet J; Favier L; Lagrange A; Peignaux-Casasnovas K; Mettey L; Tharin Z; Foucher P; Martin E
    Cancer Radiother; 2020 Jul; 24(4):279-287. PubMed ID: 32439358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy.
    Crvenkova S; Pesevska M
    J BUON; 2015; 20(3):775-81. PubMed ID: 26214630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
    Stinchcombe TE; Morris DE; Lee CB; Moore DT; Hayes DN; Halle JS; Rivera MP; Rosenman JG; Socinski MA
    J Thorac Oncol; 2008 Mar; 3(3):250-7. PubMed ID: 18317067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognosis of locally advanced non small cell lung cancer treated with three dimentional conformal radiotherapy].
    Zhu XZ; Wang LH; Ou GF; Zhou ZM; Chen DF; Xiao ZF; Feng QF; Zhang HX; Wang M; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):748-53. PubMed ID: 18396686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
    Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
    Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.